VIZIMPRO®

Drug Information Related Patent

Hold Company

PFIZER

Learn More

Dosage and Administration

TABLET;ORAL

Specification

15MG; 30MG; 45MG

Indication

VIZIMPRO® is indicated for first-line therapy in patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation.

Use

Instructions for Use

API

DACOMITINIB

API Structure

We Supply

DACOMITINIB

Note:

Facility GMP
DMF

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
10596162	2026/2/2
10603314	2026/2/2
7772243	2028/8/26
8623883	2025/5/5

API Patent

Patent No	Expiration Date
7772243	2028/8/26
8623883	2025/5/5

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION